How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes

SIMPLE SUMMARY: TP53 mutations are seen in 5–10% of de novo MDS and AML, but 25–40% of therapy-related MDS and AML. Despite the addition of recent drugs to the common regimen and improvement of post transplantation survival, these particular myeloid malignancy subtypes remain a challenge for hematol...

Descripción completa

Detalles Bibliográficos
Autores principales: Loschi, Michael, Fenaux, Pierre, Cluzeau, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496940/
https://www.ncbi.nlm.nih.gov/pubmed/36139679
http://dx.doi.org/10.3390/cancers14184519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496940/
https://www.ncbi.nlm.nih.gov/pubmed/36139679
http://dx.doi.org/10.3390/cancers14184519

Ejemplares similares